What Is HLA-B57 and Why Is Testing Important?

HLA-B57 is a variant of a gene that helps your immune system distinguish your own cells from infected or abnormal ones, and testing for it matters primarily because carrying a specific subtype, HLA-B*57:01, puts you at high risk of a severe allergic-like reaction to the HIV drug abacavir. That single drug-gene interaction has made HLA-B*57:01 screening one of the most successful examples of pharmacogenetic testing in routine clinical practice. But the story of HLA-B57 extends well beyond one medication, touching HIV control, hepatitis C clearance, liver injury from certain antibiotics, and even human evolution under infectious disease pressure.

How HLA-B57 Fits Into Your Immune System

Your cells carry surface proteins that act like display cases, presenting tiny fragments of whatever is happening inside the cell to passing immune cells. These display proteins belong to the major histocompatibility complex class I (MHC-I) family, and in humans the genes encoding them are called HLA-A, HLA-B, and HLA-C. Together they produce six slightly different versions of these display proteins on every nucleated cell in your body, and each version is especially good at grabbing and showing off certain peptide fragments. When a killer T cell spots something unfamiliar in one of those displays, it destroys the cell.¹

The HLA genes are among the most variable in the entire human genome. HLA-B alone has thousands of recognized variants, and HLA-B57 is one cluster within that diversity. The subtypes within HLA-B57 (like B*57:01, B*57:02, and B*57:03) differ from each other by just a few amino acids, but those small differences change which peptide fragments get displayed. That specificity is what makes one subtype linked to a dangerous drug reaction while another is not.

The Abacavir Hypersensitivity Reaction

Abacavir is a nucleoside reverse transcriptase inhibitor used in several common HIV treatment regimens. Roughly five to eight percent of people taking it without prior genetic screening develop a hypersensitivity reaction, which can include fever, rash, gastrointestinal symptoms, and respiratory distress. In severe cases or on re-exposure after stopping, the reaction can be life-threatening. Research established that this reaction is strongly associated with carrying the HLA-B*57:01 allele.¹

The mechanism is unusually well understood for a drug allergy. Abacavir physically nestles into the peptide-binding groove of the HLA-B*57:01 protein, specifically into a pocket called the F pocket. By occupying that space, the drug changes which self-peptides the protein can grab and display. Suddenly, the cell surface shows peptide fragments that were never displayed before. Passing T cells see these unfamiliar fragments and react as though the body’s own tissues are foreign, launching an immune attack that resembles an organ-transplant rejection response.²

This explanation resolved a long-standing mystery about why certain drug allergies are tied to specific HLA types. It is not that the immune system is recognizing the drug directly. Instead, the drug reshapes what the immune system sees on its own cells, triggering a misguided self-attack. The insight has influenced how researchers think about other HLA-linked drug reactions as well.

Why Screening Before Prescribing Abacavir Became Standard

Once the link between HLA-B*57:01 and abacavir hypersensitivity was confirmed, clinical guidelines shifted rapidly. The Clinical Pharmacogenetics Implementation Consortium (CPIC) issued guidelines recommending that clinicians test for HLA-B*57:01 before starting abacavir, and that carriers of the allele should not receive the drug.³ This is now standard practice in high-resource settings and is one of the few pharmacogenetic tests that most HIV clinicians consider non-negotiable before prescribing.

Economic analyses have consistently found the testing to be cost-effective. One model estimated that over the first 60 days of treatment, prospective screening cost about $17 per patient and avoided roughly 537 hypersensitivity reactions per 10,000 patients. Over a lifetime horizon, screening-informed abacavir use was actually less costly than simply starting everyone on an alternative drug like tenofovir, because abacavir regimens themselves tend to be cheaper.⁴ A separate analysis calculated the cost per quality-adjusted life year gained at around $36,700, which falls well within thresholds typically considered acceptable in healthcare systems.⁵

The practical result is straightforward: if you test negative for HLA-B*57:01, abacavir is an option. If you test positive, your doctor chooses a different backbone drug. The test effectively eliminates immunologically confirmed hypersensitivity reactions in screened populations.

How the Test Actually Works

Several laboratory methods can identify HLA-B*57:01, and the choice often depends on the resources available. Traditional approaches include sequence-specific oligonucleotide (SSO) typing and sequence-specific primer (SSP) PCR, which are standard tools in HLA laboratories. More recently, real-time PCR assays using hydrolysis probes have been developed specifically for HLA-B*57:01 screening. One such assay demonstrated 100% accuracy in distinguishing B*57:01-positive from B*57:01-negative samples across 75 clinical specimens when compared against reference laboratory typing.⁶

A key challenge in screening is distinguishing HLA-B*57:01 from closely related subtypes like B*57:03 and B*58:01, which do not carry the same abacavir hypersensitivity risk. Simpler screening methods like quantitative PCR can detect all B*57 subtypes with high sensitivity (above 99%) and a perfect negative predictive value, meaning they essentially never miss a true positive. However, they sometimes flag B*57:03 carriers as positive, giving a false alarm. More refined methods like SSP PCR with additional resolution steps achieve both sensitivity and specificity above 99%.⁷ In practice, a two-step approach works well: a rapid initial screen catches anyone with a B*57 allele, and a confirmatory test pins down the exact subtype if the screen is positive.

The Testing Gap in Resource-Limited Settings

While HLA-B*57:01 testing before abacavir is routine in wealthier countries, it remains out of reach in many parts of sub-Saharan Africa, South and Southeast Asia, and other regions with high HIV burdens. The equipment needed for molecular HLA typing is expensive, requires trained technicians, and depends on cold-chain reagent supply. This creates a cruel paradox: the places where abacavir is most needed as an affordable, heat-stable component of HIV regimens are often the places where the safety test cannot be performed.⁸

Researchers have been working on cheaper, simpler alternatives. One approach uses isothermal amplification, a technique that works at a single constant temperature and doesn’t require the expensive thermal cycling equipment that standard PCR needs. The goal is a point-of-care test that a clinician could run in a doctor’s office or rural health post without specialized training.⁹ These rapid tests are still being validated, but they represent a meaningful step toward closing the gap between guidelines and reality.

Population Differences in Allele Frequency

How common HLA-B*57:01 is varies substantially across populations. In people of European descent, the allele frequency sits at roughly five to eight percent. In some South Asian populations it can be somewhat higher, while in many East Asian and African populations it is much less common. These ethnogeographic differences have real consequences for whether universal pre-prescription screening makes economic sense in a given country or whether the allele is rare enough that a different approach might be warranted.¹⁰

When the allele is very rare in a population, you have to screen a large number of patients to prevent a single hypersensitivity case. That can shift the cost-effectiveness calculation, though the severity of the reaction (potentially fatal on re-exposure) keeps the argument for testing strong even in low-prevalence settings. Most major HIV treatment guidelines worldwide now recommend the test regardless of ethnicity, partly because individual ancestry is a poor predictor of any single person’s genotype.

Flucloxacillin and Drug-Induced Liver Injury

Abacavir is not the only medication linked to HLA-B*57:01. Flucloxacillin, a penicillin-type antibiotic widely used in Europe and Australia for staphylococcal skin infections, can cause drug-induced liver injury (DILI) in a small fraction of users. A genome-wide association study found that HLA-B*57:01 was by far the strongest genetic risk factor, with carriers facing roughly 80 times the odds of developing flucloxacillin-related liver damage compared to non-carriers.¹¹

Despite that striking odds ratio, routine HLA-B*57:01 screening before prescribing flucloxacillin has not become standard practice. The reason is partly about numbers: flucloxacillin-induced DILI is rare in absolute terms (affecting a small fraction per hundred thousand prescriptions), so even among carriers the overall risk remains low. The 80-fold increase in relative risk sounds alarming, but 80 times a very small number is still a small number. This contrasts with abacavir, where the hypersensitivity reaction affects a sizeable percentage of carriers who take the drug. The flucloxacillin finding does, however, illustrate that HLA-B*57:01 shapes immune reactivity in ways that extend beyond a single drug class.

HLA-B57 and Natural Control of HIV

Separate from any drug interaction, HLA-B57 has attracted intense research interest because of its association with so-called elite controllers of HIV. These are the rare individuals (well under one percent of people living with HIV) who maintain undetectable viral loads without ever taking antiretroviral therapy. The HLA-B*57 allele, along with the closely related B*58:01, is dramatically overrepresented in this group.¹²

The reason appears to involve the specific viral targets that HLA-B57 presents to killer T cells. HLA-B57 and B*58:01 are particularly good at grabbing and displaying peptides from a conserved region of the HIV Gag protein, especially an epitope called TW10. This region is structurally important for the virus: it helps stabilize part of the viral capsid. When the immune system mounts a strong T-cell response against TW10, the virus faces intense pressure to mutate that region to escape detection.¹³

The dominant escape mutation, called T242N, does allow the virus to dodge immune recognition, but at a steep price. Structural studies show that the amino acid at position 242 plays a critical role in stabilizing a helix within the p24 capsid protein. When the virus mutates it, replication capacity drops substantially.¹⁴ The virus can eventually recover some of that lost fitness by accumulating additional compensatory mutations elsewhere in Gag, but that process takes time and isn’t guaranteed to succeed.¹⁵ In the meantime, the weakened virus is easier for the immune system to contain. This tug-of-war between immune escape and viral fitness cost helps explain how some HLA-B57 carriers keep HIV at bay for years or even decades.

Carrying HLA-B57 does not guarantee elite controller status, though. Plenty of B57-positive individuals still progress to AIDS without treatment. The allele is strongly associated with better outcomes, but it works alongside other factors, both genetic and otherwise, that researchers are still sorting out.

Connections to Hepatitis C

The protective reach of HLA-B57 may extend to other viral infections. In hepatitis C, carrying HLA-B*57 has been associated with roughly twice the rate of spontaneous viral clearance compared to non-carriers.¹⁶ Since many people living with HIV are co-infected with hepatitis C, researchers investigated whether HLA-B57 might explain why HIV controllers seem to clear hepatitis C more often than HIV progressors do.

The answer turned out to be more nuanced. One study found that HIV controllers cleared hepatitis C at similar rates whether or not they carried HLA-B*57, with about a third of controllers in each group spontaneously clearing the virus. That suggests other host factors associated with controller status, beyond HLA-B57 itself, contribute to hepatitis C clearance.¹⁷ The relationship between HLA types and hepatitis C outcomes is real but involves a broader web of immune factors than just one allele.

HLA-B57 and Human Evolution Under Disease Pressure

One of the more striking findings around HLA-B57 concerns its role in human evolution, not over millennia but potentially within decades. A study of a mother-child cohort from the pre-antiretroviral era (1998–2005) in a sub-Saharan African population found that HLA-B alleles categorized as protective, including B*57, slowed AIDS progression and reduced vertical transmission from mother to child. The odds of vertical transmission among mothers carrying protective alleles were about 43% lower compared to the baseline.¹⁸

Modeling based on those data projected that without antiretroviral therapy, the proportion of the population carrying any protective HLA-B allele would have risen from about 23% to 42% over just 45 years (1990–2035), while disease-susceptible alleles would have declined from 28% to 18% over the same period. That is remarkably fast evolutionary change for a human population. The widespread rollout of antiretroviral therapy, by keeping HIV-positive individuals alive regardless of HLA type, effectively blocks this natural selection. From a public health perspective that is unambiguously a good thing, but from an evolutionary biology standpoint, it is a fascinating natural experiment that illustrates how a single infectious disease could reshape human immune genetics within a few generations.

HLA-B57 and Autoimmune Disease Susceptibility

The same aggressive immune surveillance that makes HLA-B57 good at fighting certain viruses may come with trade-offs in the form of autoimmune vulnerability. Various HLA-B alleles have been studied in connection with psoriasis, psoriatic arthritis, and other conditions where the immune system attacks the body’s own tissues. Population studies have found associations between particular HLA alleles and psoriasis risk, though the exact role of HLA-B57 specifically remains tangled up with nearby genes that tend to be inherited together as a block.¹⁹

The broader pattern is a recurring theme in immunogenetics: an HLA variant that confers an advantage against one threat often increases vulnerability to another. HLA alleles linked to strong viral control tend to show up in studies of autoimmune conditions, allergies, and drug hypersensitivity. It is a built-in tension in the immune system’s design, and HLA-B57 sits right at the intersection of it. Whether you experience the protective side or the reactive side depends on what your immune system encounters over the course of your life, and whether any drugs you take happen to fit into the binding groove of that particular protein.